BioSpace News Archive

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced the closing of the equity investment announced on June 20, 2022.

Select Medical Corporation and Inova Health System announced a joint venture to own and operate the first critical illness recovery hospital in Northern Virginia.

Eliaz Therapeutics Inc, a therapeutic apheresis company, was awarded its second NIH grant, an SBIR phase 2 grant for $1.7M.

Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), today announced approximately $13 million of procurement orders for oral TPOXX (tecovirimat), including $11 million for initial procurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region that has an established contract for oral TPOXX (tecovirimat).

Jason Bottiglieri held senior leadership roles within the cardiovascular device market including Invatec (acquired by Medtronic), Spectranetics (acquired by Philips) and Cordis, a Johnson & Johnson company.

Bodyport , a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors.

Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, presented its first set of data showing its novel biologic, XTMAB-16, has the potential to reduce the formation of sarcoidosis granulomas.

Ancora Heart, Inc. a company developing a novel device-based therapy to address heart failure (HF), today announced that Mark Miles has joined the company as Chief Commercial Officer (CCO).

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new preclinical data for STAR-0215 in two presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2022 Hybrid Congress which takes place from July 1-3, 2022.